MS Path 2 Care

AVON, Colo., – March 5, 2018 – Can Do Multiple Sclerosis (Can Do MS) announced today the launch of MS Path 2 Care, a new educational initiative that aims to empower people affected by multiple sclerosis (MS) to be active partners in their healthcare experience. The program was developed in collaboration with Sanofi Genzyme, the specialty care global business unit of Sanofi. It focuses on the importance of shared decision making in MS care and encouraging people with MS to work collaboratively with their support partners and their broader healthcare teams.

“At Can Do MS, we believe that it is critical for people with MS to be proactive and engaged in managing their own care. That is why we are so excited by the launch of MS Path 2 Care, which provides information and tools that can help address a wide range of challenges from MS,” said Anne Gilbert, the organization’s Director of Programs.

MS Path 2 Care aims to help patients take charge of managing the full scope of their disease and enrich relationships most critical to their MS journeys. The initiative brings together experts from across the MS community, including people living with MS, healthcare providers specializing in MS, and national advocacy organizations.

“We are happy to be collaborating with Can Do MS on MS Path 2 Care, an important, new resource for people living with MS and their support partners,” said Christina Rossi, North America Commercial Lead, MS, at Sanofi Genzyme. “We believe it is important for people impacted by MS to take an active role in the management of their disease and are committed to supporting programs that help drive better and more informed care.”

The initiative’s website,, features four educational modules, each providing insights and stories from people impacted by MS. To inform the development of these modules, Can Do MS and Sanofi Genzyme worked closely with the Society for Participatory Medicine, an organization focused on promoting collaboration and communication among patients, caregivers, and healthcare professionals to foster patient engagement and education. Topics explored in the modules include:

“The patient and the healthcare provider are both experts in MS; they are partners in care. The provider is an expert in the science, and the patient lives with the disease every day. Having been on both sides of the conversation, I know that each has a unique and complementary perspective, so it is vital that developing a care plan is a collaborative effort,” said program participant Stephanie Buxhoeveden, MSCN, MSN, FNP-BC, who is living with MS. “From this standpoint, a resource like MS Path 2 Care is so valuable because it provides MS patients with the tools they need to start a constructive dialogue with their healthcare providers and empowers them to take charge of their own disease journey.”

An estimated 400,000 people in the United States are living with MS, a serious, life-long, progressive, immune-mediated inflammatory and neurodegenerative disease in which the immune system attacks the central nervous system.

March is designated MS Awareness Month, dedicated to increasing knowledge about the signs and symptoms of the disease, as well as its burden on people living with MS and their support partners.

To access the educational modules, as well as other helpful resources, people impacted by MS can visit

About MS Path 2 Care
MS Path 2 Care is a collaborative initiative developed by Can Do MS, Sanofi Genzyme, and The Society for Participatory Medicine. It focuses on the importance of shared decision making between people living with MS, their care partners, and their healthcare team, and encourages strong and collaborative relationships with those involved in MS care.

About Can Do MS
A national nonprofit organization based in Avon, Colorado, Can Do MS delivers health and wellness education programs on exercise, nutrition, symptom management, and motivation to help families thrive. For more information, visit the organization’s website at or call 800-367-3101.

Anne Gilbert, Can Do MS 
800-367-3101 ext. 1281